3,4-dihydroxybenzamidoxime | 95933-72-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 3,4-dihydroxybenzamidoxime
• 英文别名: amidox；N',3,4-trihydroxybenzenecarboximidamide
• CAS: 95933-72-5
• 化学式: C₇H₈N₂O₃
• 分子量: 168.152
• InChiKey: JOAASNKBYBFGDN-UHFFFAOYSA-N

物化性质

• 沸点：
  392.9±52.0 °C(Predicted)
• 密度：
  1.52±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  99.1
• 氢给体数：
  4
• 氢受体数：
  4

安全信息

• 海关编码：
  2925290090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P330,P362,P403+P233,P501
• 危险性描述：
  H302,H312,H332
• 储存条件：
  存储条件为2-8℃，建议使用惰性气体保护。

反应信息

• 作为反应物：
  描述：

  3,4-dihydroxybenzamidoxime 在 盐酸羟胺 作用下， 以 甲醇 为溶剂， 反应 24.0h， 生成 N,N',3,4-tetrahydroxybenzene-1-carboximidamide
  参考文献：
  名称：

  Methods for treating or preventing neuroinflammation or autoimmune diseases

  摘要：

  本文揭示了核糖核苷酸还原酶抑制剂、包含核糖核苷酸还原酶抑制剂的组合物，以及使用核糖核苷酸还原酶抑制剂治疗和/或预防自身免疫疾病和神经炎症性疾病的方法。

  公开号：

  US09526707B2
• 作为产物：
  描述：

  3,4-二羟基苯腈 在 硫酸羟胺 、 sodium hydroxide 作用下， 以 水 为溶剂， 反应 18.0h， 生成 3,4-dihydroxybenzamidoxime
  参考文献：
  名称：

  Methods for treating or preventing neuroinflammation or autoimmune diseases

  摘要：

  本文揭示了核糖核苷酸还原酶抑制剂、包含核糖核苷酸还原酶抑制剂的组合物，以及使用核糖核苷酸还原酶抑制剂治疗和/或预防自身免疫疾病和神经炎症性疾病的方法。

  公开号：

  US09526707B2

文献信息

• Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
  申请人：ELFORD, Howard L.

  公开号：EP2030615A2

  公开（公告）日：2009-03-04

  Ribonucleotide reductase inhibitors, compositions comprising ribonucleotide reductase inhibitors, and methods for treating and/or preventing autoimmune diseases and neuroinflammatory diseases with the ribonucleotide reductase inhibitors.

  核糖核苷酸还原酶抑制剂、包含核糖核苷酸还原酶抑制剂的组合物，以及用核糖核苷酸还原酶抑制剂治疗和/或预防自身免疫性疾病和神经炎性疾病的方法。
• Therapeutic DNA vaccination
  申请人：——

  公开号：US20020022034A1

  公开（公告）日：2002-02-21

  A method for genetic immunization comprises administering a highly active antiretroviral therapy to control viral replication, and then administering a transcutaneous DNA vaccine.

  基因免疫方法包括使用高活性抗逆转录病毒疗法来控制病毒复制，然后使用经皮 DNA 疫苗。
• Hydroxyurea treatment for spinal muscular atrophy
  申请人：——

  公开号：US20030040543A1

  公开（公告）日：2003-02-27

  The invention features a method of modulating SMN exon 7 expression in a subject by administering hydroxyurea to the subject.

  本发明的特点是通过对受试者施用羟基脲来调节受试者体内 SMN 外显子 7 表达的方法。
• Composition and methods for treatment of HIV infection
  申请人：——

  公开号：US20040228839A1

  公开（公告）日：2004-11-18

  Method of inhibiting or treating Human Immunodeficiency Virus (HIV) infection, comprising administering to a patient in need thereof an effective amount of a pharmaceutically acceptable composition comprising a PEG-ASNase compound or asparaginase, and optionally at least one compound selected from the group consisting of protease inhibitor compounds, ribonucleotide reductase inhibitor compounds and HIV reverse transcriptase inhibitor compounds.

  抑制或治疗人类免疫缺陷病毒（HIV）感染的方法，包括向有需要的患者施用有效量的药学上可接受的组合物，该组合物包含PEG-ASNase化合物或天冬酰胺酶，以及可选的至少一种选自由蛋白酶抑制剂化合物、核糖核苷酸还原酶抑制剂化合物和HIV逆转录酶抑制剂化合物组成的组的化合物。
• Synthesis of 1,2,4-oxadiazole derivatives: anticancer and 3D QSAR studies
  作者：Ankur Vaidya、Shweta Jain、Br Prashantha Kumar、Shashank K. Singh、Sushil Kumar Kashaw、Ram Kishore Agrawal

  DOI：10.1007/s00706-020-02553-1

  日期：2020.3

  A 3D QSAR study was performed on 1,2,4-oxadiazole derivatives using the [(SW) kNN MFA], CoMFA, and CoMSIA techniques. On the basis of 3D QSAR outcomes, new molecules were designed by substituting different substituents. These designed compounds were synthesized and confirmed their synthesis by spectroscopic techniques. The synthesized compounds were screened for their anticancer activity against different cancer cell lines. Compound 2-[3-(pyridine-4-yl)-1,2,4-oxadiazol-5-yl]benzo[d]thiazole showed equipotent (IC50 = 4.96 mu M) as 5-fluorouracil (IC50 = 3.2 mu M) against colon (CaCo-2) cancer cell line, and compound [2-[3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl]benzo[d]thiazol-4-yl]methanol showed equipotent activity (IC50 = 0.35 mu M) as compared to 5-fluorouracil (IC50 = 0.23 mu M) against colorectal (DLD1) cancer cell line. Compound 2-[3-(3,4-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]benzo[d]thiazole was found to be 4-5 less potent (IC50 = 19.40 mu M) as paclitaxel (IC50 = 4.10 mu M) against breast (T47D) cancer cell line, and compound 4-[5-(benzo[d]thiazol-2-yl)-1,2,4-oxadiazol-3-yl]benzene-1,2-diol was found about 10 times less potent (IC50 = 15.7 mu M) than mitomycin (IC50 = 1.50 mu M) against prostate (PC-3) cancer cell line. These results disclose the discovery of new 1,2,4-oxadiazole-based anticancer drugs. Graphic abstract